Technological Advances in Regenerative Medicine

Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mesenchymal and hematopoietic stem cells, a transition caused by the fast-paced developments in iPSC research. Developments in technology platform help improve overall stem cell therapy and selection and reduce overall costs. Emerging companies are establishing newer cell isolation, characterization, and screening processes to ensure constant cell viability and maintenance.

Industry players increasingly adopt artificial intelligence and machine learning technologies for stem cell imaging, real-time tracking, and entering new disease areas. Stem cell therapies have huge potential in treating oncology, neurological conditions, and cardiac conditions, apart from rare diseases. Private investments and collaborations continue to drive stem cell R&D and push the clinical trial pipelines across various diseases.

This report covers incremental technological improvements and the new platforms that stakeholders have designed for stem cell therapy developments in induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and human embryonic stem cells.

Key Questions This Study Addresses:

• What is the current landscape of stem cell therapy, and what are the overall trends?
• What are the technology developments improving stem cell therapy R&D?
• Which companies are adopting new technology platforms to scale stem cell therapy R&D?
• What is the investment and partnership ecosystem in stem cell therapy development?